GDUFA Guidance Offers Peek At Generic Drug User Fee Levels
A new guidance includes preliminary estimates of backlog, application and drug master file fees under the new generic drug user fee program. However, the agency must wait for Congress to pass an FY 2013 appropriations bill or continuing resolution with language allowing it to collect the new revenue.
You may also be interested in...
Public Citizen asks whether CMS policy could have helped prevent the drug contamination at New England Compounding Center as Senate committee wants more information on states’ regulatory practices.
After the House and Senate question whether FDA needs more authority to regulate compounders like the New England Compounding Center, Sen. Lamar Alexander suggests clearly designating who has jurisdiction may be the answer.
Congress will explore causes and potential policy solutions to the meningitis outbreak at the New England Compounding Center in back-to-back hearings, but any legislation increasing FDA regulatory authority faces a long road.